<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font6" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="7" family="Giovanni-Book" color="#000000"/>
<text top="41" left="55" width="175" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>International Seminars in Surgical Oncology</i></text>
<text top="41" left="230" width="27" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2005, </text>
<text top="41" left="257" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>2</b></text>
<text top="41" left="262" width="13" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:12</text>
<text top="41" left="391" width="163" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.issoonline.com/content/2/1/12</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="151" segment_no="12" tag_type="text">Page 2 of 7</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="152" segment_no="13" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">The most common sarcoma for which HDT and AuSCT</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">has been investigated is the Primitive Neuroectodermal</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">Ectodermal Tumor (PNET) family of tumours which</text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">includes Ewing's sarcoma (ES). Indeed, the median age at</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">diagnosis of PNET is14 years with 90% of patients being</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">under the age of 20 ye<a href="">ars.[4] I</a>n adults with PNET, the 5-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">year overall survival (OS) following conventional-dose</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">therapy is between 38–60% while the progression-free</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">survival (PFS) is 27–59%.<a href=""> [5-7] Co</a>nversely, adult and</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">paediatric patients who fail to achieve a complete</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">response following surgery and conventional-dose chem-</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">otherapy are considered incurable and those with distant</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">metastases have only 9% – 33% long term su<a href="">rvival.[8]</a></text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">With respect to the role of HDT with AuSCT, no rand-</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="2" tag_type="text">omized studies have been performed and most published</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="2" tag_type="text">studies have included predominantly paediatric patients.</text>
<text top="275" left="55" width="26" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="2" tag_type="text">[<a href="">9-16]</a></text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">Similarly, there is limited data on the role of HDT and</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">AuSCT for osteos<a href="">arcoma.[17] Aga</a>in, studies to date have</text>
<text top="322" left="55" width="224" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">predominantly involved paediatric patients<a href="">.[1,18,19</a>]</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="9" tag_type="text">The most common soft tissue sarcoma (STS) in children is</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="9" tag_type="text">rhabdomyosarcoma (RMS). Rare in adults, the disease</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="9" tag_type="text">free survival at 5 years of adult STS (different histologies)</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="9" tag_type="text">is approximately 10%. <a href="">[20-25] In </a>general, aggressive local</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="9" tag_type="text">therapy consisting of maximum tumor bulk reduction</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="9" tag_type="text">with surgery, with or without radiotherapy, is the corner-</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="9" tag_type="text">stone of initial management and patients with STS who</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="9" tag_type="text">are rendered disease free after surgery have a superior DFS</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="9" tag_type="text">than those who are inop<a href="">erable.[26</a>] However, many</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="9" tag_type="text">patients with STS are diagnosed with advanced-stage of</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="9" tag_type="text">the disease and/or complete surgical resection of the</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="9" tag_type="text">tumor is not feasible. Moreover, 40 to 60% of patients,</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="9" tag_type="text">even after a primarily curative local therapy, will develop</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="9" tag_type="text">metastases most frequently occurring within 2 to 3 years,</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="9" tag_type="text">and they will ultimately die of the diseas<a href="">e.[27] </a>Adult</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="9" tag_type="text">patients with RMS treated with conventional-dose therapy</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="9" tag_type="text">have an even worse prognosis than child<a href="">ren.[28]</a> The role</text>
<text top="545" left="55" width="221" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="9" tag_type="text">of HDT and AuSCT for RMS remains un<a href="">clear.[11,29]</a></text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="11" tag_type="text">Given the results with conventional-dose therapy, the role</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="11" tag_type="text">of HDT with AuSCT for sarcomas has largely been</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="11" tag_type="text">explored for patients with relapsed disease or those at</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="11" tag_type="text">high-risk of relapse. Patients with adult STS generally are</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="11" tag_type="text">poorly responsive to conventional-dose chemotherapy,</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="11" tag_type="text">with doxorubicin and ifosfamide being the only available</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="11" tag_type="text">agents showing response rates of greater than 20%. Com-</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="11" tag_type="text">bination regimens generally do not add efficacy, but do</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="11" tag_type="text">add toxici<a href="">ty.[21,24,27] </a>For both agents, a dose-response</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="11" tag_type="text">relationship has been shown. Despite this theoretical</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="11" tag_type="text">rationale, the benefit of HDT is far from established in</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="11" tag_type="text">paediatric population, let alone for adult patients with</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="11" tag_type="text">sarcomas, with only a few studies reported and with small</text>
<text top="721" left="55" width="151" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="11" tag_type="text">patient nu<a href="">mbers.[9-11,17,18,27,30]</a></text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">Of the studies reported to date, improved survival rates</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">appear to be achieved for patients who achieve a complete</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">remission (CR) prior to HDT or for those where total</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">resection of tumor is feasible either before or after HDT.</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text"><a href="">[10-12,26,30] Convers</a>ely, HDT with AuSCT appears not</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">to improve outcome for PNET patients with metastatic</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">disease at presentation<a href="">.[13-16,31] He</a>re we report our</text>
<text top="169" left="313" width="93" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="3" tag_type="text">experience in treating </text>
<text top="169" left="407" width="23" height="9" font="font5" id="p1_t68" reading_order_no="65" segment_no="3" tag_type="text"><i>adult </i></text>
<text top="169" left="430" width="125" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="3" tag_type="text">patients with PNET, osteosar-</text>
<text top="181" left="313" width="66" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="3" tag_type="text">coma and RMS.</text>
<text top="204" left="313" width="115" height="10" font="font6" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="title"><b>Materials and methods</b></text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="5" tag_type="text">A retrospective review of adult patients who underwent</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="5" tag_type="text">HDT with AuSCT for sarcoma since 1992 at our institute</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="5" tag_type="text">was performed. Toxicity was assessed according to the</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="5" tag_type="text">World Health Organisation scale. Survival curves were</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="5" tag_type="text">generated according to the Kaplan-Meier method with OS</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="5" tag_type="text">and PFS calculated from the date of first stem cell</text>
<text top="286" left="313" width="38" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="5" tag_type="text">infusion.</text>
<text top="310" left="313" width="36" height="10" font="font6" id="p1_t79" reading_order_no="76" segment_no="7" tag_type="title"><b>Results</b></text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="8" tag_type="text">A total of 17 patients underwent HDT and AuSCT and</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="8" tag_type="text">their characteristics are presented in Table <a href="">1 </a>and included</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="8" tag_type="text">ES (9), PNET (1), osteosarcoma (5) and RMS (2). There</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="8" tag_type="text">were 14 males and 3 females with the median age at time</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="8" tag_type="text">of AuSCT of 24 years (range 20–41 years). HDT was</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="text">administered as part of initial treatment (8), of which</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="text">only one was in CR, five in PR, one with progressive dis-</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="8" tag_type="text">ease (ProD) and one with stable disease (SD); in first</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="8" tag_type="text">relapse (7), of which four were in CR, one in PR and two</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="8" tag_type="text">with ProD; fourth relapse (1) who was in CR. Disease sta-</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="8" tag_type="text">tus immediately prior to HDT (following conventional-</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="8" tag_type="text">dose chemotherapy and/or surgery and/or radiotherapy)</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="8" tag_type="text">was CR (6), partial remission (PR) (6), stable disease (SD)</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="8" tag_type="text">(1) and ProD (4). The source of autologous stem cells was</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="8" tag_type="text">peripheral blood for 15 patients and bone marrow for two</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="8" tag_type="text">patients. Eleven patients underwent a planned tandem</text>
<text top="510" left="313" width="45" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="8" tag_type="text">transplant.</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="10" tag_type="text">HDT regimens were selected depending on prior therapy</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="10" tag_type="text">or involvement in specific clinical trials. Patients with</text>
<text top="557" left="313" width="211" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="10" tag_type="text">osteosarcoma received carboplatin (700 mg/m</text>
<text top="556" left="524" width="4" height="6" font="font7" id="p1_t100" reading_order_no="97" segment_no="10" tag_type="text">2</text>
<text top="557" left="528" width="26" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="10" tag_type="text">) and</text>
<text top="568" left="313" width="100" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">etoposide (750 mg/m</text>
<text top="568" left="413" width="4" height="6" font="font7" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">2</text>
<text top="568" left="417" width="4" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">)</text>
<text top="568" left="421" width="3" height="6" font="font7" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">a</text>
<text top="568" left="424" width="130" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="10" tag_type="text">. Four patients subsequently</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="10" tag_type="text">received a second HDT and AuSCT with the same regimen</text>
<text top="592" left="313" width="129" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="10" tag_type="text">(2) or melphalan (180 mg/m</text>
<text top="591" left="442" width="4" height="6" font="font7" id="p1_t109" reading_order_no="106" segment_no="10" tag_type="text">2</text>
<text top="592" left="446" width="108" height="9" font="font4" id="p1_t110" reading_order_no="107" segment_no="10" tag_type="text">) and etoposide (60 mg/</text>
<text top="604" left="313" width="14" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="10" tag_type="text">kg)</text>
<text top="603" left="327" width="6" height="6" font="font7" id="p1_t112" reading_order_no="109" segment_no="10" tag_type="text">b </text>
<text top="604" left="332" width="222" height="9" font="font4" id="p1_t113" reading_order_no="110" segment_no="10" tag_type="text">(2). Patients with PNET/ES received a single course of</text>
<text top="615" left="313" width="123" height="9" font="font4" id="p1_t114" reading_order_no="111" segment_no="10" tag_type="text">melphalan (180 mg/m</text>
<text top="615" left="436" width="4" height="6" font="font7" id="p1_t115" reading_order_no="112" segment_no="10" tag_type="text">2</text>
<text top="615" left="440" width="4" height="9" font="font4" id="p1_t116" reading_order_no="113" segment_no="10" tag_type="text">)</text>
<text top="615" left="444" width="3" height="6" font="font7" id="p1_t117" reading_order_no="114" segment_no="10" tag_type="text">c</text>
<text top="615" left="447" width="108" height="9" font="font4" id="p1_t118" reading_order_no="115" segment_no="10" tag_type="text">(2) or radionuclide</text>
<text top="627" left="313" width="43" height="9" font="font4" id="p1_t119" reading_order_no="116" segment_no="10" tag_type="text">Samarium</text>
<text top="627" left="357" width="13" height="6" font="font7" id="p1_t120" reading_order_no="117" segment_no="10" tag_type="text">153 </text>
<text top="627" left="372" width="32" height="9" font="font4" id="p1_t121" reading_order_no="118" segment_no="10" tag_type="text">EDTMP</text>
<text top="627" left="404" width="4" height="6" font="font7" id="p1_t122" reading_order_no="119" segment_no="10" tag_type="text">d</text>
<text top="627" left="408" width="138" height="9" font="font4" id="p1_t123" reading_order_no="120" segment_no="10" tag_type="text">(1) or carboplatin (700 mg/m</text>
<text top="627" left="546" width="4" height="6" font="font7" id="p1_t124" reading_order_no="121" segment_no="10" tag_type="text">2</text>
<text top="627" left="550" width="4" height="9" font="font4" id="p1_t125" reading_order_no="122" segment_no="10" tag_type="text">)</text>
<text top="639" left="313" width="114" height="9" font="font4" id="p1_t126" reading_order_no="123" segment_no="10" tag_type="text">and etoposide (750 mg/m</text>
<text top="638" left="428" width="4" height="6" font="font7" id="p1_t127" reading_order_no="124" segment_no="10" tag_type="text">2</text>
<text top="639" left="431" width="4" height="9" font="font4" id="p1_t128" reading_order_no="125" segment_no="10" tag_type="text">)</text>
<text top="638" left="435" width="3" height="6" font="font7" id="p1_t129" reading_order_no="126" segment_no="10" tag_type="text">e</text>
<text top="639" left="438" width="116" height="9" font="font4" id="p1_t130" reading_order_no="127" segment_no="10" tag_type="text">(1) or carboplatin (AUC =</text>
<text top="651" left="313" width="108" height="9" font="font4" id="p1_t131" reading_order_no="128" segment_no="10" tag_type="text">21), thiotepa (900 mg/m</text>
<text top="650" left="421" width="4" height="6" font="font7" id="p1_t132" reading_order_no="129" segment_no="10" tag_type="text">2</text>
<text top="651" left="425" width="120" height="9" font="font4" id="p1_t133" reading_order_no="130" segment_no="10" tag_type="text">) and etoposide (750 mg/m</text>
<text top="650" left="544" width="4" height="6" font="font7" id="p1_t134" reading_order_no="131" segment_no="10" tag_type="text">2</text>
<text top="651" left="548" width="4" height="9" font="font4" id="p1_t135" reading_order_no="132" segment_no="10" tag_type="text">)</text>
<text top="650" left="552" width="2" height="6" font="font7" id="p1_t136" reading_order_no="133" segment_no="10" tag_type="text">f</text>
<text top="662" left="313" width="193" height="9" font="font4" id="p1_t137" reading_order_no="134" segment_no="10" tag_type="text">(1) or tandem cycles with ifosfamide (12 g/m</text>
<text top="662" left="506" width="4" height="6" font="font7" id="p1_t138" reading_order_no="135" segment_no="10" tag_type="text">2</text>
<text top="662" left="510" width="44" height="9" font="font4" id="p1_t139" reading_order_no="136" segment_no="10" tag_type="text">), carbopl-</text>
<text top="674" left="313" width="185" height="9" font="font4" id="p1_t140" reading_order_no="137" segment_no="10" tag_type="text">atin (AUC = 20) and etoposide (60 mg/kg)</text>
<text top="674" left="498" width="5" height="6" font="font7" id="p1_t141" reading_order_no="138" segment_no="10" tag_type="text">g </text>
<text top="674" left="503" width="51" height="9" font="font4" id="p1_t142" reading_order_no="139" segment_no="10" tag_type="text">followed by</text>
<text top="686" left="313" width="116" height="9" font="font4" id="p1_t143" reading_order_no="140" segment_no="10" tag_type="text">and melphalan (180 mg/m</text>
<text top="685" left="429" width="4" height="6" font="font7" id="p1_t144" reading_order_no="141" segment_no="10" tag_type="text">2</text>
<text top="686" left="432" width="118" height="9" font="font4" id="p1_t145" reading_order_no="142" segment_no="10" tag_type="text">) and etoposide (60 mg/kg)</text>
<text top="685" left="550" width="4" height="6" font="font7" id="p1_t146" reading_order_no="143" segment_no="10" tag_type="text">b</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t147" reading_order_no="144" segment_no="10" tag_type="text">(3);or tandem cycles with two cycles of carboplatin (700</text>
<text top="709" left="313" width="26" height="9" font="font4" id="p1_t148" reading_order_no="145" segment_no="10" tag_type="text">mg/m</text>
<text top="709" left="339" width="4" height="6" font="font7" id="p1_t149" reading_order_no="146" segment_no="10" tag_type="text">2</text>
<text top="709" left="342" width="137" height="9" font="font4" id="p1_t150" reading_order_no="147" segment_no="10" tag_type="text">) and etoposide (750 mg/m2)</text>
<text top="709" left="480" width="5" height="6" font="font7" id="p1_t151" reading_order_no="148" segment_no="10" tag_type="text">a </text>
<text top="709" left="486" width="68" height="9" font="font4" id="p1_t152" reading_order_no="149" segment_no="10" tag_type="text">(1); or tandem</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t153" reading_order_no="150" segment_no="10" tag_type="text">cycles with carboplatin (AUC = 21), thiotepa (900 mg/</text>
</page>
</pdf2xml>
